US FDA approves Sanofi-AstraZeneca’s preventive RSV therapy for babies
The U.S. Food and Drug Administration (FDA) said on Monday it had approved Sanofi and partner AstraZeneca’s antibody therapy to prevent respiratory syncytial virus (RSV) in infants and toddlers.